TrivarX Appoints Emeritus Research for Phase 1 Study

Summary by 6ix AI

The appointment secures essential clinical infrastructure and experienced personnel for the upcoming study, which aims to evaluate the safety and pharmacokinetics of a stable isotope-based imaging platform. Initial participant enrollment is targeted for the first quarter of the following year, with preliminary results expected shortly thereafter, pending regulatory approvals.

Written by 6ix AI from the company’s filing. How 6ix writes summaries